drugset / Trial / NCT01437592

Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects

NCT01437592

Phase 1 Completed 24 enrolled Novo Nordisk A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial was conducted in Asia. The aim of this trial was to investigate the pharmacokinetic properties (the effect of the investigated drug on the body) of NN1250 (insulin degludec) in healthy Chinese subjects.

Timeline

Start
2011-09-06
Primary completion
2011-11-22
Completion
2011-11-22

Publications

  • Background Pei H, Jiang J, Bardtrum L, Haahr H. Pharmacokinetic properties of insulin degludec in healthy Chinese subjects. Diabetes Manag 2019;9(1):20-7

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin degludec Protein / enzyme biologic Subcutaneous

Indications